M&A Radar Tracker

Healthcare Deals Reshaping the Middle East & Africa

M&A Healthcare Radar | August 2026

The Deal Signal: Healthcare Capital Is Moving From Expansion to Consolidation

The healthcare M&A landscape is entering a more strategic phase. Across the Middle East and Africa, investors are increasingly looking beyond individual hospitals and conventional acquisitions toward platform building, regional consolidation, pharmaceutical localization, specialist healthcare networks and technology-enabled care.

This regional trend is taking place against a stronger global healthcare M&A environment. PwC identifies three major forces shaping health-industry dealmaking in the second half of 2026: consumerisation of healthcare, pharmaceutical companies rebuilding their pipelines, and technology-led transactions. (PwC)

1. Saudi Arabia: Healthcare Consolidation Moves Into Its Next Phase

Saudi Arabia remains one of the most important healthcare M&A markets in the Middle East.

The country’s healthcare transformation is creating an environment in which scale, operational sophistication and specialized clinical capabilities are increasingly valuable. Healthcare groups are expanding not only through greenfield hospitals, but also through acquisitions, strategic partnerships and platform consolidation.

One of the most significant recent transactions was Fakeeh Care’s SAR 1.6 billion acquisition of Al Fagih hospitals, demonstrating the continuing appetite for consolidation among Saudi healthcare providers. (M&A Community Portal)

Another important signal is the entry of international healthcare capital into the Saudi market. In 2025, Italy’s GKSD announced an agreement to acquire a controlling stake in SURGCA, a day-surgery and ambulatory-care centre in Riyadh, representing its entry into Saudi healthcare. (Arab News)

M&A Radar View

The Saudi market is gradually moving from:

Hospital expansion → healthcare platforms → specialized services → integrated ecosystems.

The next targets are likely to include:

• Ambulatory and day-surgery platforms
• Specialty hospitals
• Diagnostics
• Fertility and women’s health
• Oncology
• Home healthcare
• Rehabilitation
• Digital health
• Medical technology
• Pharmaceutical manufacturing
• Healthcare logistics and supply-chain infrastructure

🔴 Radar signal: VERY HIGH

Saudi Arabia is increasingly becoming not merely a healthcare investment market, but a regional healthcare consolidation hub.

2. Saudi Arabia–Brazil: Cross-Border Oncology Creates a New M&A Corridor

One of the more interesting healthcare transactions recently tracked in the region involves the oncology sector.

Brazilian oncology specialist Oncoclínicas agreed to sell its 51% stake in the Saudi SMTC joint venture, with the transaction involving Saudi partners Al Faisaliah Group Holding and Advanced Drug Company for Pharmaceuticals. (M&A Community Portal)

The significance goes beyond the individual transaction. It illustrates a growing phenomenon: Clinical expertise is becoming an M&A asset.

Healthcare groups in the Middle East are increasingly interested in acquiring or partnering with organizations that bring:

• Specialized clinical protocols
• International medical expertise
• Physician networks
• Technology
• Clinical governance
• Brand reputation
• Research capabilities
• International patient flows

M&A Radar View

The future Middle East healthcare transaction may increasingly look like:

Saudi capital + international clinical expertise + regional operating platform.

That is a very different model from traditional hospital acquisition.

🔴 Radar signal: VERY HIGH

3. Africa: Pharmaceuticals May Become the First Major Consolidation Wave

Africa’s healthcare M&A story remains less mature than the Gulf’s, but the strategic opportunity is enormous.

One of the clearest recent examples is Strides Pharma’s agreement to acquire and in-license a portfolio of branded generic pharmaceutical products from Sandoz across Sub-Saharan Africa.

The transaction covers markets including Ghana, Nigeria and Kenya, with products spanning anti-infectives, cardiovascular medicines and dermatology. The transaction has an initial consideration of approximately US$12 million and is expected to close by September 2026, subject to regulatory approvals. (The Economic Times)

The strategic logic is particularly important. This is not simply an acquisition of brands. It is an acquisition of: Market access + distribution + physician relationships + pharmacy penetration + established products + regional scale.

Following the transaction, Strides expects to significantly strengthen its position in Sub-Saharan Africa. (Express Pharma)

M&A Radar View

Africa could experience a pharmaceutical consolidation cycle in which international and regional companies acquire:

• Established generic portfolios
• Local pharmaceutical manufacturers
• Distribution companies
• Specialty pharmaceutical businesses
• Contract manufacturing capabilities
• Consumer healthcare brands
• Medical distribution platforms

The most attractive targets may not necessarily be the largest companies. They may be the companies with regulatory registrations, established distribution networks and strong local market access.

🔴 Radar signal: VERY HIGH

4. Egypt: The Next Consolidation Opportunity?

Egypt remains one of the most strategically important healthcare markets in Africa because of its population scale, physician base, medical infrastructure and potential to serve as a regional healthcare hub.

However, Egypt’s healthcare M&A opportunity is evolving. The next wave is unlikely to be driven exclusively by large hospital acquisitions. Instead, investors may increasingly look toward:

Diagnostics → outpatient networks → specialty centres → fertility → oncology → home healthcare → pharmaceutical manufacturing → healthcare technology.

The underlying attraction is the possibility of creating multi-site healthcare platforms rather than acquiring isolated assets.

M&A Radar View

Egypt could become particularly attractive to investors seeking a combination of:

• Large addressable population
• Lower operating costs
• Medical talent
• Healthcare demand
• Medical tourism potential
• Pharmaceutical manufacturing capabilities
• Regional export opportunities

🟠 Radar signal: HIGH

5. The UAE: From Domestic Healthcare Market to Global Healthcare Capital Platform

The UAE continues to play a unique role in the regional healthcare M&A ecosystem. Its importance is not limited to the size of its domestic healthcare market.

Abu Dhabi and Dubai increasingly function as capital, management, technology and international expansion platforms.

The regional strategy of UAE-based healthcare groups demonstrates an increasingly global approach to healthcare investment. PureHealth’s acquisition of the UK’s largest private healthcare group in 2023 for approximately $1.2 billion remains an important example of Gulf healthcare capital moving into international healthcare assets. (Arab News)

The implication is significant for M&A. Gulf healthcare companies are no longer necessarily looking for assets only within their home markets. They are increasingly asking:

Where can we acquire clinical capabilities, brands and operating expertise that can be brought back into our regional ecosystem?

🔴 Radar signal: VERY HIGH

6. The Global Benchmark: India Shows Where Healthcare Consolidation Can Go

Where the Middle East and Africa are heading can be seen in more mature emerging healthcare markets. India provides a particularly important benchmark.

In August 2026, KKR agreed to acquire Medicover’s Indian hospital operations for approximately US$1.39 billion, marking KKR’s third major hospital acquisition in India in three years. (The Economic Times)

The transaction demonstrates the power of the platform consolidation model. Instead of acquiring individual hospitals opportunistically, financial investors are building large healthcare networks with:

• Geographic scale
• Centralized procurement
• Clinical specialization
• Digital infrastructure
• Brand power
• Physician networks
• Operating efficiencies

This is precisely the type of model that could become increasingly relevant in Saudi Arabia, Egypt and selected African markets.

7. Global Healthcare M&A: The Capital Is Getting More Selective

The global healthcare M&A market remains active, but investors are becoming more selective.

Baker Tilly reported that global healthcare M&A deal value increased 38% in 2025 to approximately US$546.7 billion, one of the strongest years since the post-pandemic peak. (Baker Tilly)

Meanwhile, healthtech remains a major transaction category. Corum reports 149 healthtech M&A deals in Q1 2026, with disclosed transaction value of approximately US$22.7 billion. Private equity represented 31% of transactions. (Corum Group)

Pharmaceutical and biotechnology transactions are also driving the market. PwC’s 2026 outlook identifies the pharmaceutical pipeline, consumerisation and technology as major forces shaping healthcare dealmaking. (PwC)

And July 2026 demonstrated the continuing appetite for large healthcare transactions: GlobalData data cited by Express Pharma put healthcare deal value at US$29.5 billion across 87 deals, up 55.2% year-on-year. (Express Pharma)

8. What Are Buyers Actually Looking For?

The M&A radar suggests that healthcare investors are increasingly dividing targets into six strategic categories.

9. The New M&A Currency: Clinical Governance

There is another factor that deserves greater attention. Healthcare M&A cannot be evaluated only through EBITDA, revenue growth and market share.

The quality of clinical governance increasingly determines whether an acquisition creates long-term value.

A healthcare platform with weak clinical governance can create significant post-acquisition risks:

• Patient safety issues
• Regulatory exposure
• Physician attrition
• Reputation damage
• Litigation
• Poor clinical outcomes
• Integration failure

Therefore, the next generation of healthcare due diligence should increasingly combine:

Financial Due Diligence + Commercial Due Diligence + Regulatory Due Diligence + Clinical Due Diligence + Technology Due Diligence.

This is particularly important in emerging markets where healthcare regulation, physician ownership structures and operating models can vary significantly between jurisdictions.

10. M&A Radar Tracker — August 2026

Tashawer M&A View

The most important conclusion from the current healthcare M&A landscape is that consolidation is becoming more sophisticated.

• The first generation of healthcare M&A was primarily about buying assets.
• The second generation was about buying revenue.
• The emerging third generation is about buying capabilities.

A hospital group may acquire a specialty centre not because of its beds, but because of its physicians. A pharmaceutical company may acquire a local business not because of its factory, but because of its regulatory registrations and distribution network. A healthcare investor may acquire a healthtech company not because of its current revenue, but because its technology can transform an existing healthcare platform. And a Gulf investor may acquire an international healthcare company not simply to enter another country, but to import clinical expertise, governance, technology and operating know-how into its wider healthcare ecosystem.

For investors, the question is therefore no longer:

“What healthcare company should we buy?”

It is:

“What capability will healthcare leaders need to control five years from now—and which company already owns it?”

That is where the next generation of healthcare M&A opportunities is likely to emerge.

---

Source base: PwC, Baker Tilly, Reuters, GlobalData reporting, Express Pharma, Economic Times and regional M&A market sources. Transaction status and values should be independently confirmed before investment or publication decisions. (PwC)